Informazione Regolamentata n. 20279-18-2026	Data/Ora Inizio Diffusione 30 Luglio 2026 11:57:53	Euronext Growth Milan

Societa'	:	VALTECNE
Utenza - referente	:	VALTECNENSS01 - Ottonello Adolfo
Tipologia	:	3.1
Data/Ora Ricezione	:	30 Luglio 2026 11:57:53
Data/Ora Inizio Diffusione	:	30 Luglio 2026 11:57:53
Oggetto	:	THE BOARD OF DIRECTORS OF VALTECNE S.P.A. REVIEWED SALES REVENUES AS AT 30 JUNE 2026

Testo del comunicato

Vedi allegato

PRESS RELEASE

THE BOARD OF DIRECTORS OF VALTECNE S.P.A. REVIEWED SALES REVENUES AS AT 30 JUNE 2026

CONSOLIDATED REVENUES GROWING TO € 19.6 MILLION

THE MEDICAL BUSINESS LINE IS CONFIRMED AS THE MAIN REFERENCE MARKET, WHILE THE INDUSTRIAL BUSINESS LINE ACCELERATES

Berbenno di Valtellina (SO), 30 July 2026 – The Board of Directors of **Valtecne S.p.A.** (ISIN IT0005532525, ticker VLT.IM) – a company operating in the field of high-precision mechanics for medical devices and industrial applications – met today and reviewed and approved the sales revenues as at June 30, 2026, which have not been audited.

Paolo Mainetti, Chief Executive Officer of Valtecne S.p.A., commented: *"The results for the first half confirm the strength of our business model and the validity of the strategy we are pursuing. Revenue growth was driven by the Medical segment, which remains our main reference market. The slight decline recorded in the Medical segment is exclusively attributable to timing dynamics in revenue recognition related to stock production contracts, and does not reflect any change in demand or business outlook. At the same time, the positive performance of the Industrial business line allowed us to make the best use of our production capacity.*

This is also the context for the agreement announced with G Square, a transaction that represents an important acknowledgment of the industrial value built up over the years and that will allow us to accelerate our growth. We look at the second half of the year with confidence, ready to seize the development opportunities the market continues to offer".

Below is the breakdown of consolidated revenues for the first six months of 2026 compared with the corresponding period of 2025, by business line.

CONSOLIDATED					
SALES REVENUES (€/thousands)	**30/06/2026**	**% of total**	**30/06/2025**	**% of total**	**Chg %**
Medical Business line	14,225	72.6%	14,592	75.1%	-2.5%
Industrial Business line	5,359	27.4%	4,831	24.9%	10.9%
Total	**19,584**	**100%**	**19,422**	**100%**	**0.8%**

At consolidated level, in the first half of 2026 **total revenues** amounted to **€ 19.6 million**, a slight increase (+0.8%) compared with € 19.4 million as at 30 June 2025. Specifically, the **Medical business line** generated revenues of **€ 14.2 million**, a slight decrease (-2.5%) compared with the first half of 2025, maintaining a 72.6% share of the total. This decrease was solely due to the dynamics of stock production contracts, which affected the timing profile of revenue recognition. The **Industrial business line**, on the other hand, recorded revenues of **€ 5.4 million**, up 10.9% compared with the same period of 2025. This increase reflects a strategic choice by the Group to maximize the saturation of production capacity during the period, benefiting operating margins. Despite this increase, the Group's focus remains on the medical sector, in line with corporate strategy, with an overall share of turnover close to 73%.

* * *

This press release is also available on the Company's website www.valtecne.com (section "Investors/Financial Press Releases") and on www.emarketstorage.it.

* * *

***About* Valtecne**

Founded in 1983, Valtecne is a leading company in high-precision mechanics. It manufactures components used in the medical sector – particularly surgical instruments for orthopedics and implantable components – as well as in various industrial sectors such as power transmission, automotive, and energy. As of 31 December 2025, Valtecne reported Production Value of € 37.3 million and Adjusted EBITDA of € 9.7 million, corresponding to an EBITDA margin of 26.0%.

Contacts:

Euronext Growth Advisor – CFO SIM S.p.A.
ecm@cfosim.com
Phone. + 02 30343 1

Specialista – MIT SIM
trading-desk@mitsim.it
Phone +39 02 305 612 70

Ufficio Stampa Corporate – CDR Communication
Martina Zuccherini martina.zuccherini@cdr-communication.it

Fine Comunicato n.20279-18-2026	Numero di Pagine: 4